-
Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period CNS Drugs (IF 6.0) Pub Date : 2024-03-15 Kathrine Bang Madsen, Mette Bliddal, Charlotte Borg Skoglund, Henrik Larsson, Trine Munk-Olsen, Malene Galle Madsen, Per Hove Thomsen, Veerle Bergink, Chaitra Srinivas, Jacqueline M. Cohen, Isabell Brikell, Xiaoqin Liu
-
Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis CNS Drugs (IF 6.0) Pub Date : 2024-03-15 Rosa Cortese, Giovanna Testa, Francesco Assogna, Nicola De Stefano
-
Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options CNS Drugs (IF 6.0) Pub Date : 2024-03-14
Abstract Compulsive sexual behavior disorder (CSBD) has recently been recognized as a psychiatric disorder. Pharmacological treatments for CSBD have received little study and thus have limited empirical support. The main objective of the present work is to review existing literature on the efficacy of different drugs on the symptomatology of CSBD, including the subtype of problematic pornography use
-
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis CNS Drugs (IF 6.0) Pub Date : 2024-03-01 Yue Qiao, Jian Gu, Miao Yu, Yuewei Chi, Ying Ma
-
The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study CNS Drugs (IF 6.0) Pub Date : 2024-02-29
Abstract Introduction The administration of opioids can be followed by enduring neuroplastic changes in the peripheral and central nervous systems. This remodeling can lead to opioid-induced hyperalgesia, causing an increased sensitivity to painful stimuli. The description of opioid-induced changes in the somatosensory system has seldom been described in the setting of opioid agonist therapy in the
-
Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis CNS Drugs (IF 6.0) Pub Date : 2024-02-29 Anastasiia D. Shkodina, Mainak Bardhan, Hitesh Chopra, Onyekachi Emmanuel Anyagwa, Viktoriia A. Pinchuk, Kateryna V. Hryn, Anzhelina M. Kryvchun, Dmytro I. Boiko, Vinay Suresh, Amogh Verma, Mykhailo Yu. Delva
-
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study CNS Drugs (IF 6.0) Pub Date : 2024-02-28 Lucienne Costa-Frossard França, Virginia Meca Lallana, Andrés Labiano-Fontcuberta, Rosario Blasco, Enric Monreal, María Luisa Martínez Ginés, Clara Aguirre, Julia Sabin Muñoz, Susana Sainz de la Maza, Juan Pablo Cuello, Carolina Díaz-Pérez, Juan Luis Chico García, Alberto Lozano Ros, Fernando Rodríguez Jorge, Susana Martínez Martínez, José Manuel García Domínguez
-
SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants CNS Drugs (IF 6.0) Pub Date : 2024-02-28 Andreas W. Wolff, Jörg Peine, Josef Höfler, Gabriela Zurek, Claus Hemker, Paul Lingor
-
Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data CNS Drugs (IF 6.0) Pub Date : 2024-02-23
Abstract Andexanet alfa is a specific reversal agent for factor Xa inhibitors with immediate reversal of their anticoagulant effect. Andexanet alfa is currently approved for use in patients treated with rivaroxaban and apixaban who have life-threatening or uncontrolled bleeding. New data from both controlled clinical trials and real-world experience are continuously being published, providing greater
-
Unmet Needs in Psychodermatology: A Narrative Review CNS Drugs (IF 6.0) Pub Date : 2024-02-22 Rachel E. Christensen, Mohammad Jafferany
Psychodermatology, the multidisciplinary field that explores the intricate interplay between the mind and the skin, has gained increasing recognition over the past decade. However, several knowledge gaps and unmet needs persist in the field. The objective of this narrative review was to investigate the unmet needs in the field of psychodermatology as they pertain to medical training, treatment, research
-
Benzodiazepines for the Treatment of Seizure Clusters CNS Drugs (IF 6.0) Pub Date : 2024-02-15 Patricia E. Penovich, Vikram R. Rao, Lucretia Long, Enrique Carrazana, Adrian L. Rabinowicz
-
Targeting Pannexin-1 Channels: Addressing the ‘Gap’ in Chronic Pain CNS Drugs (IF 6.0) Pub Date : 2024-02-14 Brendan B. McAllister, Sierra Stokes-Heck, Erika K. Harding, Nynke J. van den Hoogen, Tuan Trang
-
The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis CNS Drugs (IF 6.0) Pub Date : 2024-02-01 Yongbo Ma, Xiangtao Nie, Geke Zhu, Wenjing Qi, Lei Hao, Xiuming Guo
-
Trends in Pregabalin Use and Prescribing Patterns in the Adult Population: A 10-Year Pharmacoepidemiologic Study CNS Drugs (IF 6.0) Pub Date : 2024-01-25
Abstract Background and Objective Pregabalin is steadily gaining popularity worldwide, with epidemiological studies indicating an increase in labeled, off-labeled, and recreational uses. In Israel, pregabalin prescriptions are not regulated by the controlled substances legislations, prompting a need to examine its usage trends for potential policy adjustments. The objective of this study was to assess
-
Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center CNS Drugs (IF 6.0) Pub Date : 2024-01-25
Abstract Background Intrathecal administration of amphotericin B represents an important adjunctive therapy for management of severe fungal meningitis. Intrathecal preparations have traditionally used amphotericin B deoxycholate. Liposomal amphotericin B is an alternative formulation with good clinical outcomes as systemic therapy, but scant data exist investigating intrathecal use. Objective The aim
-
Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study CNS Drugs (IF 6.0) Pub Date : 2024-01-24 Pedro J Serrano-Castro, Teresa Ramírez-García, Pablo Cabezudo-Garcia, Guillermina Garcia-Martin, Juan De La Parra
-
Treatment of Sleep, Motor and Sensory Symptoms with the Orexin Antagonist Suvorexant in Adults with Idiopathic Restless Legs Syndrome: A Randomized Double-Blind Crossover Proof-of-Concept Study CNS Drugs (IF 6.0) Pub Date : 2024-01-21 Diego Garcia-Borreguero, Alba Garcia Aragón, Brian Moncada, Sofia Romero, Juan José Granizo, Sonia Quintas, María Castillo
-
Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review CNS Drugs (IF 6.0) Pub Date : 2024-01-18 Sarah Smessaert, Johan Detraux, Franciska Desplenter, Marc De Hert
-
Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future CNS Drugs (IF 6.0) Pub Date : 2024-01-11 Salvatore Crisafulli, Brigida Boccanegra, Massimo Carollo, Emanuela Bottani, Paola Mantuano, Gianluca Trifirò, Annamaria De Luca
-
Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia CNS Drugs (IF 6.0) Pub Date : 2024-01-08 Xin Li, Chong Ye, Wanyi Zhang, Miaomiao Jia, Gang Wang
-
Effect of Levetiracetam on Cognition: A Systematic Review and Meta-analysis of Double-Blind Randomized Placebo-Controlled Trials CNS Drugs (IF 6.0) Pub Date : 2023-12-15 Chia-Yen Lin, Meng-Chia Chang, Hong-Jie Jhou
-
Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia CNS Drugs (IF 6.0) Pub Date : 2023-12-14 Chuanjun Zhuo, Qiuyu Zhang, Lina Wang, Xiaoyan Ma, Ranli Li, Jing Ping, Jingjing Zhu, Hongjun Tian, Deguo Jiang
Schizophrenia is a complex psychotic disorder with co-occurring conditions, including insulin resistance and type 2 diabetes (T2D). It is well established that T2D and its precursors (i.e., insulin resistance) are more prevalent in patients with schizophrenia who are treated with antipsychotics, as well as in antipsychotic-naïve patients experiencing their first episode of psychosis, compared with
-
Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies CNS Drugs (IF 6.0) Pub Date : 2023-11-29 René Fuertig, Markus Goettel, Lena Herich, Josef Hoefler, Sabrina T. Wiebe, Vikas Sharma
-
Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial CNS Drugs (IF 6.0) Pub Date : 2023-11-29 Haiqing Song, Yuan Wang, Qingfeng Ma, Huisheng Chen, Bo Liu, Yi Yang, Jianguo Zhu, Shigang Zhao, Xiaoping Jin, Yongqiu Li, Yanyong Wang, Runxiu Zhu, Liandong Zhao, Junyan Liu, Wuwei Feng, Rui Liu, Xunming Ji, Yuping Wang
-
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males CNS Drugs (IF 6.0) Pub Date : 2023-11-29 Markus Goettel, Rene Fuertig, Salome Rebecca Mack, Stefan Just, Vikas Sharma, Andreas Wunder, Johan den Boer
-
Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study CNS Drugs (IF 6.0) Pub Date : 2023-11-22 Mohammed Abou Kaoud, Ran Nissan, Amitai Segev, Avi Sabbag, David Orion, Elad Maor
-
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study CNS Drugs (IF 6.0) Pub Date : 2023-11-24 Valeria Caponnetto, Antonio Russo, Marcello Silvestro, Alessandro Tessitore, Roberto De Icco, Gloria Vaghi, Grazia Sances, Cristina Tassorelli, Carlo Baraldi, Flavia Lo Castro, Simona Guerzoni, Maria Pia Prudenzano, Adriana Fallacara, Martino Gentile, Raffaele Ornello, Agnese Onofri, Andrea Burgalassi, Alberto Chiarugi, Francesco De Cesaris, Antonio Granato, Alfonsina Casalena, Marina De Tommaso, Edoardo
-
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review CNS Drugs (IF 6.0) Pub Date : 2023-11-24 Niloufar Pouyan, Farnaz Younesi Sisi, Alireza Kargar, Milan Scheidegger, Roger S. McIntyre, Jonathan D. Morrow
-
Context is a Critical for Psychoactive Drug Effects. CNS Drugs (IF 6.0) Pub Date : 2023-11-24 Kyle T Greenway
-
Current Insights into Diagnosing and Treating Neurotuberculosis in Adults CNS Drugs (IF 6.0) Pub Date : 2023-11-17 Sofiati Dian, Ahmad Rizal Ganiem, Lindsey HM te Brake, Arjan van Laarhoven
-
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012–2021) from a University Hospital in Germany CNS Drugs (IF 6.0) Pub Date : 2023-11-18 Leonore Purwien, Susanne Schubert-Bast, Matthias Kieslich, Michael W. Ronellenfitsch, Michael Merker, Marcus Czabanka, Laurent M. Willems, Felix Rosenow, Adam Strzelczyk
-
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials CNS Drugs (IF 6.0) Pub Date : 2023-11-16 Laila Aboulatta, Lara Haidar, Ahmed Abou-Setta, Nicole Askin, Rasheda Rabbani, Alekhya Lavu, Payam Peymani, Ryan Zarychanski, Sherif Eltonsy
-
A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance CNS Drugs (IF 6.0) Pub Date : 2023-11-09 Thomas R. Arkell, Brooke Manning, Luke A. Downey, Amie C. Hayley
-
A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal-Onset Epilepsy CNS Drugs (IF 6.0) Pub Date : 2023-11-03 Martin Hirsch, Ilka Immisch, Susanne Knake, Andreas Schulze-Bonhage
-
Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea CNS Drugs (IF 6.0) Pub Date : 2023-10-17 Sheridan M. Hoy
Solriamfetol (SUNOSI®) is an oral selective dopamine and norepinephrine reuptake inhibitor approved in the EU and the USA for improving wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA). In phase III studies, 12 weeks’ therapy with solriamfetol within the recommended dosage range for narcolepsy (75 mg or 150 mg once daily) or
-
Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study CNS Drugs (IF 6.0) Pub Date : 2023-10-02 Yaroslav Winter, Katharina Sandner, Thomas Vieth, Gabriel Gonzalez-Escamilla, Sebastian V. Stuckrad-Barre, Sergiu Groppa
Background and Objective Status epilepticus in poststroke epilepsy is a challenging condition because of multiple vascular comorbidities and the advanced age of patients. Data on third-generation antiseizure medication (ASM) in this condition are limited. The aim of this study was to evaluate the efficacy of third-generation ASMs in the second- or third-line therapy of benzodiazepine-refractory status
-
Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials CNS Drugs (IF 6.0) Pub Date : 2023-10-04 Dania Akbar, Taeho Greg Rhee, Felicia Ceban, Roger Ho, Kayla M. Teopiz, Bing Cao, Mehala Subramaniapillai, Angela T. H. Kwan, Joshua D. Rosenblat, Roger S. McIntyre
-
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies CNS Drugs (IF 6.0) Pub Date : 2023-09-23 Luca Prosperini, Shalom Haggiag, Serena Ruggieri, Carla Tortorella, Claudio Gasperini
-
Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records CNS Drugs (IF 6.0) Pub Date : 2023-09-09 Vicente Villanueva, Cédric Laloyaux, Wendyl D’Souza, Edward Faught, Pavel Klein, Markus Reuber, Felix Rosenow, Javier Salas-Puig, Victor Soto Insuga, Adam Strzelczyk, Jerzy P. Szaflarski, Chris Chinn, Tony Daniels, Florin Floricel, David Friesen, Veronica Sendersky, Hervé Besson, Bernhard J. Steinhoff
-
Network Meta-analysis of Different Treatments for Vestibular Migraine CNS Drugs (IF 6.0) Pub Date : 2023-09-07 Jiann-Jy Chen, Bing-Syuan Zeng, Kuan-Pin Su, Yi-Cheng Wu, Yu-Kang Tu, Brendon Stubbs, Tien-Yu Chen, Bing-Yan Zeng, Yen-Wen Chen, Chih-Wei Hsu, Ping-Tao Tseng
-
Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis CNS Drugs (IF 6.0) Pub Date : 2023-09-07 Maddalena Sparaco, Luigi Carbone, Doriana Landi, Ylenia Ingrasciotta, Raffaella Di Girolamo, Giacomo Vitturi, Girolama Alessandra Marfia, Carlo Alviggi, Simona Bonavita
Multiple sclerosis (MS) predominantly affects women of fertile age. Various aspects of MS could impact on fertility, such as sexual dysfunction, endocrine alterations, autoimmune imbalances, and disease-modifying therapies (DMTs). The proportion of women with MS (wMS) requesting infertility management and assisted reproductive technology (ART) is increasing over time. In this review, we report on data
-
Comment on: "Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder". CNS Drugs (IF 6.0) Pub Date : 2023-09-01 Uday Pande,Nitin R Gaikwad,Alok Singh
-
Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder". CNS Drugs (IF 6.0) Pub Date : 2023-09-01 Maxwell Z Price,Richard L Price
-
Over the Counter Supplements for Memory: A Review of Available Evidence CNS Drugs (IF 6.0) Pub Date : 2023-08-21 Haley Hersant, Sean He, Peter Maliha, George Grossberg
In 2021, the Global Brain Health Supplement Industry Market size was valued at US$7.6 billion. It is predicted to increase to US$15.59 billion by 2030. Memory and its enhancement are a segment of the market that comprised the highest global revenue share in 2021. In the USA alone, dietary supplement sales reached US$18 billion in 2018. The US Food and Drug Administration (FDA) does not have the authority
-
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence CNS Drugs (IF 6.0) Pub Date : 2023-08-21 Antonio Inserra, Alexandre Piot, Danilo De Gregorio, Gabriella Gobbi
Anxiety disorders (ADs) represent the sixth leading cause of disability worldwide, resulting in a significant global economic burden. Over 50% of individuals with ADs do not respond to standard therapies, making the identification of more effective anxiolytic drugs an ongoing research priority. In this work, we review the preclinical literature concerning the effects of lysergic acid diethylamide (LSD)
-
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System CNS Drugs (IF 6.0) Pub Date : 2023-08-21 Emilio Perucca, Meir Bialer, H. Steve White
-
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development CNS Drugs (IF 6.0) Pub Date : 2023-08-21 Emilio Perucca, H. Steve White, Meir Bialer
The inhibitory neurotransmitter γ-aminobutyric acid (GABA) plays an important role in the modulation of neuronal excitability, and a disruption of GABAergic transmission contributes to the pathogenesis of some seizure disorders. Although many currently available antiseizure medications do act at least in part by potentiating GABAergic transmission, there is an opportunity for further research aimed
-
Efficacy and Safety of Five Broad-Spectrum Antiseizure Medications for Adjunctive Treatment of Refractory Epilepsy: A Systematic Review and Network Meta-analysis CNS Drugs (IF 6.0) Pub Date : 2023-08-17 Hecheng Wang, Haoran Wang, Yi Liu, Jing Zhao, Xuewen Niu, Lei Zhu, Xiaomin Ma, Yu Zong, Yinglin Huang, Wei Zhang, Yanshuo Han
-
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study CNS Drugs (IF 6.0) Pub Date : 2023-08-09 Meredith Castro, Samuel T. Wilkinson, Rayan K. Al Jurdi, Mary Pat Petrillo, Naim Zaki, Stephane Borentain, Dong Jing Fu, Ibrahim Turkoz, Liping Sun, Brianne Brown, Patricia Cabrera
-
GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder CNS Drugs (IF 6.0) Pub Date : 2023-08-05 Christopher Sikes-Keilp, David R. Rubinow
Premenstrual dysphoric disorder (PMDD) is characterized by the predictable onset of mood and physical symptoms secondary to gonadal steroid fluctuation during the luteal phase of the menstrual cycle. Although menstrual-related affective dysfunction is responsible for considerable functional impairment and reduction in quality of life worldwide, currently approved treatments for PMDD are suboptimal
-
The Utilization of Low Dose Naltrexone for Chronic Pain CNS Drugs (IF 6.0) Pub Date : 2023-07-28 Salomon Poliwoda, Bryant Noss, Gia Thinh D. Truong, Zachary A. Creech, Sarang S. Koushik, Ivan Urits, Omar Viswanath
Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with others, were developed with the intention of reversing the effects of opioid abuse or toxicity. Evidence has also shown that naltrexone has a benefit in preventing relapse by reducing opioid cravings and reducing symptoms of opioid withdrawal. The benefits of this drug were not
-
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis CNS Drugs (IF 6.0) Pub Date : 2023-07-25 Qian Li, Xin Li, Chong Ye, Miaomiao Jia, Tianmei Si
-
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem CNS Drugs (IF 6.0) Pub Date : 2023-07-21 Tobias Di Marco, Thomas E. Scammell, Michael Meinel, Dalma Seboek Kinter, Alexandre N. Datta, Gary Zammit, Yves Dauvilliers
-
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia CNS Drugs (IF 6.0) Pub Date : 2023-07-20 Jonathan M. Meyer, Christoph U. Correll
-
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease CNS Drugs (IF 6.0) Pub Date : 2023-07-20 Solana Leisher, Adriana Bohorquez, Marcus Gay, Victoria Garcia, Renarda Jones, Dobri Baldaranov, Michael S. Rafii
-
Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment CNS Drugs (IF 6.0) Pub Date : 2023-07-19 Valentin Loser, Jan Novy, Isabelle Beuchat, Andrea O. Rossetti
Background Valproate-induced encephalopathy (VIE) affects between 0.1% and 2.5% of patients under long-term epilepsy treatment. Its frequency and characteristics in adults with status epilepticus (SE) is, however, unknown. Objective The aim of this study was to characterize the frequency and the clinico-biological characteristics of VIE in adult SE patients. Methods We reviewed all patients included
-
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder CNS Drugs (IF 6.0) Pub Date : 2023-07-10 Maxwell Z. Price, Richard L. Price
-
The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression CNS Drugs (IF 6.0) Pub Date : 2023-06-29 Alexander L. W. Smith, Catherine J. Harmer, Philip J. Cowen, Susannah E. Murphy
-
Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System CNS Drugs (IF 6.0) Pub Date : 2023-06-21 Guadalupe Dávila, María José Torres-Prioris, Diana López-Barroso, Marcelo L. Berthier
Even though language is essential in human communication, research on pharmacological therapies for language deficits in highly prevalent neurodegenerative and vascular brain diseases has received little attention. Emerging scientific evidence suggests that disruption of the cholinergic system may play an essential role in language deficits associated with Alzheimer’s disease and vascular cognitive
-
Clonazepam Loading Dose in Status Epilepticus: Is More Always Better? CNS Drugs (IF 6.0) Pub Date : 2023-06-08 Jennifer D’Anto, Isabelle Beuchat, Andrea O. Rossetti, Jan Novy